All In Biotech

Drug Trial Radar · NCT05577312

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

39

Actual

Start

Nov 2, 2022

Primary completion

Oct 20, 2026

Study completion Jul 10, 2027

Sponsor

Lead sponsor
Bioray LaboratoriesIndustry
Sponsor type
Industry
Collaborators
First Affiliated Hospital of Guangxi Medical University; Xiangya Hospital of Central South University; Chinese Academy of Medical Sciences; Nanfang Hospital, Southern Medical University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army; Shenzhen Children's Hospital
First posted
Oct 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in subjects with Transfusion-Dependent β-Thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)

Conditions

  • Beta-Thalassemia

Interventions

  • BRL-101Drug

    CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of stem cell engrafted subjectsTime frame: Within 42 Days After BRL-101 Infusion
  2. Time to neutrophil engraftmentTime frame: Up to 12 Months After BRL-101 Infusion
  3. Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusionTime frame: Up to 12 Months After BRL-101 Infusion

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit

    Guanzhou, Guangdong, China

  • Shenzhen Children 's Hospital

    Shenzhen, Guangdong, China

  • No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.